Taxanes in the first-line chemotherapy of metastatic breast cancer: Review

European Journal of Gynaecological Oncology

Volumn 25, Issue 1, 2004, Pages 66-70

  Friedrich, M ^a   Diesing, D ^a   Villena Heinsen, C ^b   Felberbaum, R ^a   Kolberg, H C ^a   Diedrich, K ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Department of Obstetrics ^*  (Germany)

Author keywords

Breast cancer; Chemotherapy; Metastases; Taxanes

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ARTHRALGIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INFECTION; METASTASIS; MONOTHERAPY; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; REVIEW; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; VOMITING;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; NEOPLASM METASTASIS; TAXOIDS;

EID: 0842285306     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Landis S.H., Murray T., Bolden S.: "Cancer Statistics, 1999". CA. Cancer J. Clin., 1999, 49, 8.
2. Cooper R.G.: "Combination chemotherapy in hormone-resistant breast cancer". Proc. Am. Soc. Cancer Res., 1969, 10, 15.
3. Hoogstraaten B., George S.L., Samal B.: "Combination chemotherapy and adriamycin in patients with advanced breast cancer". Cancer, 1976, 38, 13.
4. Mouridsen H.T.: "Systemic therapy of advanced breast cancer". Drugs, 1992, 44, 17.
5. Ingle J.N., Maillard J.A., Schaid D.J. et al.: "Randomized trial of doxorubicin alone or combined with vincritsine and mitomycin C in women with metastatic breast cancer". Am. J. Clin. Oncol., 1989, 12, 474.
6. Neidhart J.A., Gochnour D., Roach R. et al.: "A comparison of mitoxantrone and doxorubicin in breast cancer". J. Clin. Oncol., 1986, 4, 672.
7. Vaughn C.B., Green S.J., O'Bryan R. et al.: "VP-16 + adriamycin versus adriamycin in advanced adenocarcinoma of the breast: Phase II, a randomized trial - A Southwest Oncology Group Study". Med. Pediatr. Oncol., 1988, 16, 312.
8. Henderson I.C., Allegra J.C., Woodcock T. et al.: "Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer". J. Clin. Oncol., 1989, 7, 560.
9. Hortobabyi G.N., Yap H.Y., Kau S.W. et al.: "A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer". Am. J. Clin. Oncol., 1989, 12, 57.
10. Perez D.J., Harvey V.J., Robinson B.A. et al.: "A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer". J. Clin. Oncol., 1991, 9, 2148.
11. van Oosterom A.T.: "Docetaxel (taxotere): An effective agent in the management of second-line breast cancer". Semin. Oncol., 1995, 22 (suppl. 13), 22.
12. Fumeleau P., Seidman A.D., Trudeau M.E. et al.: "Docetaxel: A new active agent in the therapy of metastatic breast cancer". Exp. Opin. Invest. Drugs, 1997, 6, 1853.
13. Trudeau M.E.: "Docetaxel (Taxotere): An overview of first-line monotherapy". Semin. Oncol., 1995, 22 (suppl. 13), 17.
14. Parideans R., Biganzoli L., Bruning P. et al.: "Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with crossover". J. Clin. Oncol., 2000, 18, 724.
15. Sledge G.W., Neuberg D., Ingle J. et al.: "Phase III trial of doxorubicin (A) versus paclitaxel (T) versus doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an Intergroup trial". Proc. Am. Soc. Clin. Oncol., 1997, 16 (abstr. 2), 1a.
16. Chan S., Friedrichs K., Noel D. et al.: "Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group". J. Clin. Oncol., 1999, 17, 2341.
17. Nabholtz J.M., Senn H.J., Bezwoda W.R. et al.: "Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy". J. Clin. Oncol., 1999, 17, 1413.
18. Sjöström J., Blomquist C., Mouridsen H. et al.: "Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomized phase III study with crossover on progression by th Scandinavian Bresat Group". Eur. J. Cancer. 1999, 35, 1194.
19. Bonneterre J., Monnier A., Roche H. et al.: "Taxotere versus 5-fluorouracil + nevelbine in patients with metastatic breast cancer as second line chemotherapy". Breast Cancer Res. Treat., 1997, 50 (abstr. 564), 162a.
20. Friedrich M., Wasemann C., Ertan A.K. et al.: "Randomized phase II study of docetaxel vs epirubicin/cyclophosphamide to optimize first-line therapy of Metastatic Breast Cancer (MBC): Preliminary results of the TIPP Study". Proc. Am. Soc. Clin. Oncol., 2002 (abstr. 2028), 21a.
21. Nabholtz J.M., Falkson G., Campos D. et al.: "A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC". Proc. Am. Soc. Clin. Oncol., 1999, 18 (abstr. 485), 125a.
22. Nabholtz J.M., Paterson A., Dirix L. et al.: "A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients with metastatic breast cancer". Proc. Am. Soc. Clin. Oncol., 2001, 20 (abstr. 83), 22a.
23. Bonneterre J.M., Dieras V., Tubiana-Hulin M. et al.: " Epirubicin/docetaxel (ET) versus 5-FU/epirubicin/cyclophosphamide (FAC) as first line chemotherapy in patients with metastatic breast cancer". Breast Cancer Res. Treat., 2001, 69 (abstr. 27), 215a.
24. Jassem J., Pienkowski T., Pluzanska A. et al.: "Doxorubicin and pacliatxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: results of randomized phase III multicenter trial". J. Clin. Oncol., 2001, 19, 1707.
25. Biganzoli L., Cufer T., Bruning P. et al.: "Doxorubicin(A)/taxol(T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy inb metastatic breast cancer: A phase III study". Proc. Am. Soc. Clin. Oncol., 2000, 19 (abstr. 282), 73a.
26. Carmichael J.: "UKCCR trial of epirubicin and cyclophosphamide (EC) versus epirubicin and taxol (ET) in the first line treatment in women withmetastatic breast cancer". Proc. Am. Soc. Clin. Oncol., 2001, 20 (abstr. 84), 22a.
27. Lück H.J., Thomssen C., Untch M. et al.: "Multicentric phase III study in first line treatment of advanced metastatic breast cancer. Epirubicin/paclitaxel (ET) versus epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group". Proc. Am. Soc. Clin. Oncol., 2000, 19 (abstr. 280), 73a.
28. O'Shaugnessy J., Miles D., Vukelja S. et al.: "Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results". J. Clin. Oncol., 2002, 20 (12), 2812.
29. Nabholtz J.M., Gelman K., Bontenbal M. et al.: "Multicenter randimized comparative study of two doses of paclitaxel in patients with metastatic breast cancer". J. Clin. Oncol., 1996, 14, 1858.
30. Peretz T., Sulkes A., Chollet P. et al.: "A multicenter randomized study of two schedules of paclitaxel (ptx) in patients with advanced breast cancer (ABC)". Eur. J. Cancer. 1995, 31a (abstr. 345), 75.
31. Winer E., Berry D., Duggan D. et al.: "Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342". Proc. Am. Soc. Clin. Oncol., 1998, 17 (abstr. 388), 101a.
32. Smith R.E., Brown A.M., Mamounas E.P. et al.: Randomized trial of 3-h versus 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast: National Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol., 1999, 17, 3403.
33. Holmes F.A., Valero V., Buzdar A.U. et al.: "Final results: randomized phase III trial of paclitaxel of 3-h versus 96-h infusion in patients (pts) with metastatic breast cancer: the long and short of it". Proc. Am. Soc. Clin. Oncol., 1998, 15 (abstr. 426), 106a.